Vanguard Group Inc. Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Vanguard Group Inc. lifted its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,684,561 shares of the biotechnology company's stock after purchasing an additional 107,635 shares during the period. Vanguard Group Inc. owned about 6.22% of Arcturus Therapeutics worth $28,587,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ARCT. KLP Kapitalforvaltning AS acquired a new stake in Arcturus Therapeutics during the 4th quarter worth approximately $71,000. SG Americas Securities LLC lifted its holdings in shares of Arcturus Therapeutics by 45.0% during the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company's stock worth $203,000 after purchasing an additional 3,705 shares during the period. Spire Wealth Management grew its stake in shares of Arcturus Therapeutics by 393.3% in the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 10,746 shares during the last quarter. Tocqueville Asset Management L.P. increased its holdings in Arcturus Therapeutics by 42.7% in the fourth quarter. Tocqueville Asset Management L.P. now owns 22,400 shares of the biotechnology company's stock valued at $380,000 after purchasing an additional 6,700 shares during the period. Finally, American Century Companies Inc. raised its position in Arcturus Therapeutics by 10.7% during the 4th quarter. American Century Companies Inc. now owns 47,018 shares of the biotechnology company's stock worth $798,000 after purchasing an additional 4,547 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Stock Up 2.2 %

NASDAQ:ARCT traded up $0.23 during trading hours on Friday, reaching $10.53. The company had a trading volume of 358,083 shares, compared to its average volume of 455,945. The business's 50-day simple moving average is $13.26 and its two-hundred day simple moving average is $16.50. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $45.00. The firm has a market cap of $285.57 million, a price-to-earnings ratio of -4.74 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The firm had revenue of $22.77 million during the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, equities analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ARCT. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, Wells Fargo & Company decreased their price target on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Arcturus Therapeutics currently has an average rating of "Buy" and a consensus target price of $59.20.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.